Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 102, Issue -, Pages 116-122Publisher
ELSEVIER
DOI: 10.1016/j.addr.2016.01.014
Keywords
Tuberculosis; Mouse model; Hollow fiber model; Pharmacokinetic/pharmacodynamic; Translational science; Trial design
Categories
Funding
- Medical Research Council [MC_UU_12023/27] Funding Source: Medline
- NIAID NIH HHS [R01 AI111992] Funding Source: Medline
- NIGMS NIH HHS [T32 GM066691] Funding Source: Medline
- MRC [MC_UU_12023/27] Funding Source: UKRI
- Medical Research Council [MC_UU_12023/27] Funding Source: researchfish
Ask authors/readers for more resources
To tackle the global TB epidemic effectively, novel treatment strategies are critically needed to shorten the duration of TB therapy and treat drug-resistant TB. Drug development for TB, stymied for decades, has enjoyed a renaissance over the past several years. However, the development of new TB regimens is hindered by the limitations in our understanding and use of preclinical models; the paucity of accurate, early surrogate markers of cure, and challenges in untangling the individual contributions of drugs to multidrug regimens in a complex, multi-compartment disease. Lack of profit motive, advocacy, and imagination has contributed mightily to the dearth of drugs we have on the shelf to treat this ancient disease. Areas that will speed the development of new regimens for TB include novel murine and in vitro pharmacodynamics models, clinical endpoints that are not culture-based, innovative clinical trial designs, and an infusion of much-needed funding. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available